Cadherins form connection between cells, facilitate communication, and serve as essential agents in the progression of multiple cancers. Over 100 cadherins have been identified and they are mainly divided into four groups: classical cadherins (CDHs), protocadherins (PCDHs), desmosomal (DSC), and cadherin-related proteins. Accumulating evidence has indicated that several members of the cadherins are involved in breast cancer development. Nevertheless, the expression profiles and corresponding prognostic outcomes of these breast cancer-related cadherins are yet to be analyzed. Here, we examined the expression levels and prognostic potential of these breast cancer-related cadherins from the specific databases viz. oncomine, gene expression profiling interactive analysis, human protein atlas, UALCAN, Kaplan–Meier Plotter, and cBioPortal. We found that the CDH2/11 levels were higher in breast cancer tissues, compared to healthy breast tissues, whereas with CDH3-5, PCDH8/10, and DSC3, the levels were lower in the former than in the latter. Additionally, for CDH1/6/13/17/23, PCDH7, and FAT4, trancript level alterations between breast cancer and healthy tissues varied across different databases. The CDH1 protein levels were elevated in breast cancer tissues versus healthy breast tissues, whereas the protein levels of CDH3/11 and PCDH8/10 were reduced in breast cancer, compared to healthy breast tissues. For CDH15 and CDH23, the expression levels paralleled tumor stage. Survival analysis, using the Kaplan–Meier Plotter database, demonstrated that elevated CDH1-3 levels correlated with diminished relapse-free survival in breast cancer patients. Alternately, enhanced CDH4-6/15/17/23, PCDH10, DSC3, and FAT4 levels estimated a rise in relapse-free survival of breast cancer patients. These data suggest CDH1-3 to be a promising target for breast cancer precision therapy and CDH4-6/15/17/23, PCDH10, DSC3, and FAT4 to be novel biomarkers for breast cancer prognosis.
SiegelRLMillerKDJemalA.Cancer statistics, 2020. CA Cancer J Clin2020;
70:7–30
2.
CardosoFHarbeckNFallowfieldLKyriakidesSSenkusE.Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2012;
23:vii11–9
3.
ChandrashekarDSBashelBBalasubramanyaSAHCreightonCJPonce-RodriguezIChakravarthiBVaramballyS.UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia2017;
19:649–58
4.
UhlénMFagerbergLHallströmBMLindskogCOksvoldPMardinogluASivertssonÅKampfCSjöstedtEAsplundAOlssonIEdlundKLundbergENavaniSSzigyartoCAOdebergJDjureinovicDTakanenJOHoberSAlmTEdqvistPHBerlingHTegelHMulderJRockbergJNilssonPSchwenkJMHamstenMvon FeilitzenKForsbergMPerssonLJohanssonFZwahlenMvon HeijneGNielsenJPonténF.Proteomics. Tissue-based map of the human proteome. Science2015;
347:1260419
5.
TangZLiCKangBGaoGLiCZhangZ.GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res2017;
45:W98–102
6.
NagyÁLánczkyAMenyhártOGyőrffyBJSr.Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 2018;8:9
7.
GaoJAksoyBADogrusozUDresdnerGGrossBSumerSOSunYJacobsenASinhaRLarssonECeramiESanderCSchultzN.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal2013;
6:11
8.
SzklarczykDGableALLyonDJungeAWyderSHuerta-CepasJSimonovicMDonchevaNTMorrisJHBorkPJensenLJMeringCV.STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res2019;
47:D607–13
9.
ShannonPMarkielAOzierOBaligaNSWangJTRamageDAminNSchwikowskiBIdekerT.Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res2003;
13:2498–504
10.
Huang daWShermanBTLempickiRA.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc4:44–57
11.
GallTMFramptonA.Gene of the month: E-cadherin (CDH1). J Clin Pathol2013;
66:928–32
12.
Pipa WellsJMShinS.JJAJoSP Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol 2014;3:434–5
13.
HeimannRLanFMcBrideRHellmanSJCr.Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res2000;
60:298–304
14.
RakhaEAbd El RehimDPinderSLewisSEllisIJH.E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology2005;
46:685–93
15.
RezaeiMFriedrichKWielockxBKuzmanovAKettelhakeALabelleMSchnittlerHBarettonGBreierG.Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression. Breast Cancer Res2012;
14:R154
16.
NakagawaMBandoYNagaoTMorimotoMTakaiCOhnishiTHondaJMoriyaTIzumiKTakahashiMJAr.Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer. Anticancer Res2011;
31:2389–93
17.
ParedesJAlbergariaAOliveiraJTJerónimoCMilaneziFSchmittF.P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res2005;
11:5869–77
18.
ParedesJMilaneziFReis-FilhoJSLeitãoDAthanazioDSchmittF-R.Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer?Pathol Res Pract2002;
198:795–801
19.
RibeiroAAlbergariaASousaBCorreiaABrackeMSerucaRSchmittFParedesJJO.Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene2010;
29:392–402
20.
RibeiroASSousaBCarretoLMendesNNobreARRicardoSAlbergariaACameselle‐TeijeiroJFGerhardRSöderbergO.P‐cadherin functional role is dependent on E‐cadherin cellular context: a proof of concept using the breast cancer model. J Pathol2013;
229:705–18
21.
SridharSRajeshCJishnuPVJayaramPKabekkoduS.Treatment. Increased expression of P-cadherin is an indicator of poor prognosis in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat2020;
179:301–13
22.
RahimiASedighiREmadi‐BaygiMHonardoostMAMowlaSJKhanahmadHNikpourP.Bioinformatics prediction and experimental validation of a novel microRNA: hsa‐miR‐B43 within human CDH4 gene with a potential metastasis‐related function in breast cancer. J Cell Biochem2020;
121:1307–16
23.
AgiostratidouGLiMSuyamaKBadanoIKerenRChungSAnzovinoAHulitJQianBBouzahzahBJCr.Loss of retinal cadherin facilitates mammary tumor progression and metastasis. Cancer Res2009;
69:5030–8
24.
FrySARobertsonCESwannRDwekM.Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion. Br J Cancer2016;
114:1019–26
25.
FrySASinclairJTimmsJFLeathemAJDwekM.A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer. Cancer Lett2013;
328:335–44
26.
LabelleMSchnittlerHJAustDEFriedrichKBarettonGVestweberDBreierGJCr.Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor β signaling. Cancer Res2008;
68:1388–97
27.
ChenJ-HHuangW-CBamoduOAChangPM-HChaoT-YHuangT.HJBc Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo. BMC Cancer 2019;19:634
28.
ZhangYYangCZhangMLiuHGongCZhangJXuSZouJKaiYLiYJO.Interleukin enhancer-binding factor 3 and HOXC8 co-activate cadherin 11 transcription to promote breast cancer cells proliferation and migration.Oncotarget2017;
8:107477–91
29.
LiYChaoFHuangBLiuDKimJHuangSJO.HOXC8 promotes breast tumorigenesis by transcriptionally facilitating cadherin-11 expression.Oncotarget2014;
5:2596–607
30.
AndrewsJKimAHensJ.The role and function of cadherins in the mammary gland. Breast Cancer Res2012;
14:203
31.
CoolMJolicoeurPJCr.Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice. Cancer Res1999;
59:2438–44
32.
YangCZhaoXCuiNLiangY.Cadherins associate with distinct stem cell-related transcription factors to coordinate the maintenance of stemness in triple-negative breast cancer. Stem Cells Int2017;5091541. doi: 10.1155/2017/5091541
33.
BosPDZhangXH-FNadalCShuWGomisRRNguyenDXMinnAJvan de VijverMJGeraldWLFoekensJAJN.Genes that mediate breast cancer metastasis to the brain. Nature2009;
459:1005–9
34.
LiA-MTianA-XZhangR-XGeJSunXCaoX-C.Protocadherin-7 induces bone metastasis of breast cancer. Biochem Biophys Res Commun2013;
436:486–90
35.
YuJKoujakSNagaseSLiCSuTWangXKeniryMMemeoLRojtmanAMansukhaniMJO.PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene2008;
27:4657–65
36.
YingJLiHSengTJLangfordCSrivastavaGTsaoSPuttiTMurrayPChanATaoQ.Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene2006;
25:1070–80
37.
OshiroMMKimCJWozniakRJJunkDJMuñoz-RodríguezJLBurrJAFitzgeraldMPawarSCCressAEDomannF.Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res2005;
7:R669–80
38.
QiCZhuYTHuLZhuY.Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer2009;
124:793–8
39.
KatohM.Function and cancer genomics of FAT family genes. Int J Oncol2012;
41:1913–8
40.
ApostolopoulouMLigonLJPO.Cadherin-23 mediates heterotypic cell-cell adhesion between breast cancer epithelial cells and fibroblasts. PLoS One2012;
7:e33289
